GHENT, Belgium – November 19th, 2021 – Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of MOLECUBES NV, a dynamic innovator in benchtop preclinical nuclear molecular imaging (NMI) systems. This acquisition strengthens Bruker’s position as a leading NMI solutions provider in preclinical and translational imaging research.
The combination of Bruker’s preclinical imaging products and global footprint with the modular benchtop CUBES™ systems of MOLECUBES will provide a broader NMI offering to further accelerate worldwide adoption of preclinical NMI in academic medical centers and biopharma companies.
Dr. Wulf I. Jung, President of the Bruker BioSpin Preclinical Imaging Division commented: “Nuclear molecular preclinical and translational imaging research are growing market segments, in which we are already recognized for high-performance simultaneous PET/MR and PET/SPECT/CT instruments, and for our PMOD™ PET data analysis software. The acquisition of MOLECUBES adds scalable benchtop instruments to our portfolio for serving the NMI preclinical research community. The synergies between our and MOLECUBES’ research and development, applications and service teams is expected to benefit our combined NMI customers worldwide.”
Professor Roel Van Holen, CEO of MOLECUBES
As a fast-growing company founded in 2015 in Ghent, Belgium, MOLECUBES develops and sells high-end PET, SPECT, and CT CUBES™ systems, with a global installated base of more than 70 systems among key opinion leaders. The modular benchtop CUBES complement Bruker’s integrated, floor-standing preclinical small animal imaging systems.
MOLECUBES will remain an innovative and agile operational team within the Bruker BioSpin Preclinical Imaging division, and MOLECUBES customers can continue communications through existing channels. MOLECUBES’ R&D and applications teams will collaborate with Bruker’s preclinical imaging experts to continuously advance NMI technology, software, workflows and applications.
MOLECUBES generated approximately Euro 5 million in FY 2020 revenue. Financial details of the acquisition were not disclosed. For more information, please visit www.bruker.com/en/products-and-solutions/preclinical-imaging
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com
MOLECUBES in Ghent, Belgium is a manufacturer of molecular imaging instrumentation for preclinical research. MOLECUBES offers a modular benchtop platform, consisting of preclinical PET, SPECT and CT CUBES™ imagers. The CUBES form a scalable platform, enabling high throughput research with a compact footprint. MOLECUBES’ mission is to advance the imaging in preclinical settings with over 70 CUBES installed in leading research facilities within academic institutions, research hospitals, and biopharma companies and contract research organizations. www.molecubes.com
The CUBES are compact micro-CT, micro-SPECT and micro-PET scanners for molecular small animal imaging, as standalone systems or in modular combinations: